Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Melanoma 31 Neoplasms 17 Multiple Myeloma 9 Thyroid Neoplasms 8 Hematologic Neoplasms 7 Thyroid Carcinoma, Anaplastic 6 Carcinoma, Non-Small-Cell Lung 6 Brain Neoplasms 6 Lymphoma 5 Glioma 5 Colorectal Neoplasms 5 Thyroid Cancer, Papillary 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Neurofibromatosis 1 3 Leukemia, Myeloid, Acute 3 Biliary Tract Neoplasms 3 Astrocytoma 3 Adenocarcinoma, Follicular 3 Uveal Melanoma 2 Uterine Cervical Neoplasms 2 Skin Neoplasms 2 Neurofibroma, Plexiform 2 Neoplasm Metastasis 2 Glioblastoma 2 Gastrointestinal Stromal Tumors 2 Colonic Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2

Interventions

trametinib 1 dabrafenib 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Malignant Neoplasm × trametinib × Clear all

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡